| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | carcinoembryonic antigen |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]
Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.
This drug was developed by Immunomedics, Inc.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab" (PDF). WHO Drug Information. 16 (1): 95. 2002.
- ^ "labetuzumab-SN-38 immunoconjugate IMMU-130". National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.